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ABSTRACT 
Objective: This study aims to develop and validate a stability-indicating hydrophilic interaction liquid chromatographic method for the 
determination of sulfaquinoxaline sodium (SQXS) in the presence of sulfaquinoxaline related compound A (SQXA) in a commercially available water 
soluble powder formulation.  
Methods:  The analytes were separated on zwitterionic hydrophilic interaction liquid chromatography (ZIC-HILIC) column with a solvent mixture of 
200mM ammonium acetate (NH4AC) solution and acetonitrile (ACN) (10:90; v/v) at pH adjusted to 5.7 by glacial acetic acid. The mobile phase flow 
was fixed at 0.5 ml/min and the analytes were monitored at 263nm at ambient temperature. Forced degradation experiments were carried out by 
exposing sulfaquinoxaline sodium standard and the water soluble powder formulation for thermal, photolytic, oxidative and acid-base hydrolytic 
stress conditions. 
Results: The results showed that SQXA and the other degradation products were fully resolved from sulfaquinoxaline sodium and thus the proposed 
ZIC-HILIC method is stability-indicating.  
Conclusion: The method was validated as per ICH and USP guidelines and found to be adequate for routine quantitative determination of SQXS in 
the presence of SQXA and other degradation impurities in commercially available water soluble powder dosage forms. 
Keywords: Validation, Stability-indicating method, Sulfaquinoxaline sodium, Sulfaquinoxaline related compound A, Water soluble powder. 
 
INTRODUCTION 
Sulfaquinoxaline sodium water soluble powder is a veterinary drug 
which contains sulfaquinoxaline sodium (SQXS) active ingredient 
and dextrose monohydrate inactive excipient. It is an oral 
baceriostatic antibiotic and coccidiostat. It is used for the prevention 
and treatment of intestinal coccidiosis in rabbits and hepatic 
coccidiosis due to Eimeria Stiedae [1].  
The main associated impurity of SQXS is the sulfaquinoxaline related 
compound A (SQXA) as shown in Figure 1. 
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Fig. 1: Structures of SQXS and SQXA 
Several sulfonamide residues including SQXS were screened and 
quantified in bovine, porcine, chicken tissues, whole egg, milk and 
veterinary drugs using HPLC or LC-MS methods [2-6]. A novel 
hydrophilic interaction liquid chromatographic (HILIC-HPLC) 
method for the simultaneous determination of SQXS combined with 
amprolium hydrochloride and vitamine K3 in powder formulation 
was validated [7]. More recently, we have developed and validated 
stability-indicating RP-HPLC method for the simultaneous 
determination of Sulfadiazine sodium (SDZS), Sulfathiazole sodium 
(STZS) and Sulfadimidine sodium (SDMS) in water soluble powder 
dosage form [8]. The current official British Pharmacopeial (BP) 
assay of sulfaquinoxaline free base is based merely on titration with 
sodium nitrite reagent and therefore is not adequate as stability 
indicating [9]. The United States Pharmacopeial (USP) assay 
however is based on the determination of sulfaquinoxaline free base 
using reversed phase chromatography and the related SQXA 
compound which is present in considerable quantity is only 
determined by TLC [10]. Moreover, water, acetonitrile, glacial acetic 
acid, tetrahydrofuran, and ammonium hydroxide were utilized in the 
mobile phase with large concentration of SQXS standard (700µg/ml) 
to enhance its sensitivity [10]. 
Although, many reversed phase HPLC methods have been reported 
for the estimation of SQXS, but there is no stability indicating 
method to determine SQXS in the presence of SQXA and other 
degradation impurities either in bulk or in pharmaceutical dosage 
forms. 
Therefore, there is a need to develop and validate a stability-
indicating quality control method that is simple, sensitive and allows 
the quantitative determination of SQXS in pharmaceutical 
formulations in the presence of SQXA or any other degradation 
products.  
The developed HILIC-HPLC method described herein successfully 
separates SQXS from SQXA, from all the degradation products and 
from the placebo simultaneously. Because analytical methods must 
be validated before use by the pharmaceutical industry, the 
proposed method was validated in accordance with ICH/USP 
guidelines [11-12]. 
MATERIALS AND METHODS 
Materials and Reagents 
The reference standard of SQXS (99.9%) (Lot no: BCBB7740V) was 
purchased from Sigma-Aldrich (Germany) and the USP SQXA (96%) 
(Lot number: F0E093) was also used. Extra pure ammonium acetate, 
glacial acetic acid, HPLC grade acetonitrile and methanol solvents, 
hydrochloric acid fuming (37%), sodium hydroxide pellets and 
hydrogen peroxide (30%), were purchased from Merck (Germany). 
High purified water was prepared by using a Millipore Milli-Q plus 
water purification system. Sulfaquinoxaline sodium soluble powder 
samples (each one gram contains 250 mg SQXS), SQXS active 
ingredient, and dextrose monohydrate excipient were kindly 
supplied by Pharmacare pharmaceutical company, Palestine. ODS 
column (250 mm 4.6 mm i.d., 5 μm particle) purchased from ACE, 
United Kingdom. A ZIC®-HILIC column (250 mm 4.6 mm, 5μm) 
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protected with a ZIC®-HILIC guard column (20mm 2.1mm, 5m) 
was purchased from Merck, Germany. 
Equipments 
The HPLC system consisted of LaChrom (Merck-Hitachi) equipped 
with model L-7100 pump, L-7200 autosampler, L-7300 column 
oven, DAD L-7450 photo diode array (PDA) detector and D-7000 
software HSM version 3.1 (Merck Hitachi, England). A double beam 
ultraviolet-visible spectrometer (PG Instruments, United Kingdom) 
was used. UV-Chamber (Model CM-10) Spectoline fluorescence 
analysis cabinet was used at 254nm.  
Chromatographic conditions 
Ammonium acetate solution (200mM) was prepared by dissolving 
3.08 g of NH4AC in high purified water and diluted up to 200 ml with 
the same solvent. 
The optimum mobile phase was prepared by mixing 200 mM NH4AC 
solution and acetonitrile (ACN) (10:90; v/v), shaken well and left till 
the mobile phase reached to the room temperature. Then the pH 
was adjusted to 5.7 with glacial acetic acid. The mobile phase was 
filtered by using 0.45 m microporous filter and was degassed by 
sonication prior to use. A wavelength of 263 nm was chosen. The 
flow rate used was 0.5 ml/minute as recommended by the column 
manufacturer. The injection volume was 20 l and the temperature 
of the column was 25° C. Total run time was about ten minutes. 
Preparation of system suitability solution 
The system suitability solution was prepared by transferring 25 mg 
of SQXS and 6 mg of SQXA reference standards into 100 ml 
volumetric flask. Then 80 ml of MeOH was added and shaken by 
mechanical means for 5 minutes, sonicated for two minute and then 
diluted up to 100 ml with the same solvent. Using volumetric 
pipette, 5 ml of this solution was transferred to 50 ml volumetric 
flask and completed to the volume using the mobile phase. 
 This solution was filtered using 0.45 m membrane filter before 
analysis. The obtained final solution contained 25µg/ml SQXS and 
6µg/ml SQXA. This solution was directly protected from light.  
Preparation of standard solution  
The standard solution was prepared by transferring 25 mg of SQXS 
reference standard into 100 ml volumetric flask. Then 80 ml of MeOH 
was added and shaken by mechanical means for 5 minutes, sonicated for 
two minute and then diluted up to 100 ml with the same solvent.  
Using volumetric pipette, 5 ml of this solution was transferred to 50 
ml volumetric flask and completed to the volume using the mobile 
phase. This solution was filtered using 0.45 m membrane filter 
before analysis. The obtained final solution contained 25µg/ml 
SQXS. This solution was directly protected from light.  
Preparation of sample solution  
The sample solution was prepared by transferring 100 mg of 
sulfaquinoxaline sodium water soluble powder into 100 ml 
volumetric flask.  
Then 80 ml of MeOH was added and shaken by mechanical means 
for 5 minutes, sonicated for two minute and then diluted up to 100 
ml with the same solvent. Using volumetric pipette, 5 ml of this 
solution was transferred to 50 ml volumetric flask and completed to 
the volume using the mobile phase. This solution was filtered using 
0.45 m membrane filter before analysis. The obtained final solution 
contained 25 µg/ml SQXS. This solution was directly protected from 
light. 
Forced degradation study 
ICH prescribed stress conditions such as acidic, basic, oxidative, 
thermal and photolytic stresses were carried out.  
Standard drug stock solutions 
Forced degradation study was conducted on solutions that were 
prepared by transferring 25 mg SQXS reference standard into four 
different 100 ml volumetric flasks. 
 Then 80 ml of MeOH was added in each flask, shaken by mechanical 
means for 5 minutes and then sonicated for two minutes until 
completely dissolved.  
These stock solutions were kept at room temperature protected 
from light and used for forced degradation studies while the thermal 
degradation solution was prepared separately as shown below. 
Acid hydrolysis 
Ten ml of 1.0 N HCl was added into one of the flasks containing SQXS 
stock solution, diluted to 100 ml with MeOH and kept at room 
temperature for 60 minutes in a dark place. Five ml of this solution 
was transferred into 50 ml volumetric flask, neutralized with 0.1 N 
NaOH and completed to volume using the mobile phase. This 
solution was filtered using 0.45 m membrane filter before analysis. 
The obtained final solution contained 25 µg/ml SQXS. 
Base hydrolysis 
Ten ml of 1.0 N NaOH was added into one of the flasks containing 
SQXS stock solution, diluted to 100 ml with MeOH and kept at room 
temperature for 60 minutes in a dark place. Five ml of this solution 
was transferred into 50 ml volumetric flask, neutralized with 0.1 N 
HCl and completed to volume using the mobile phase. This solution 
was filtered using 0.45m membrane filter before analysis. The 
obtained final solution contained 25µg/ml SQXS. 
Oxidative hydrolysis 
Ten ml of 30% H2O2 was added into one of the flasks containing 
SQXS stock solution, diluted to 100 ml with MeOH and kept at room 
temperature for 24 hours in a dark place. Five ml of this solution 
was transferred into 50 ml volumetric flask and completed to 
volume using the mobile phase. This solution was filtered using 0.45 
m membrane filter before analysis. The obtained final solution 
contained 25 µg/ml SQXS. 
Photo degradation 
One of the flasks containing SQXS stock solution was studied 
separately for its photo degradation by exposing it to UV light at 254 
nm in UV-Chamber for 36 hours and then diluted to 100 ml with 
MeOH. Five ml of this solution was transferred into 50 ml volumetric 
flask and complete to volume using the mobile phase.  
This solution was filtered using 0.45 m membrane filter before 
analysis. The obtained final solution contained 25 µg/ml SQXS. 
Thermal degradation 
The standard solution was prepared by transferring 25 mg SQXS 
reference standard that has been previously kept at 105˚C in an oven 
for 72 hours, into 100 ml volumetric flask. Then 80 ml of MeOH was 
added to the flask, shaken by mechanical means for 5 minutes and 
sonicated for two minutes until completely dissolved and then 
diluted up to 100 ml with the same solvent. Five ml of this solution 
was transferred into 50 ml volumetric flask and complete to volume 
using the mobile phase. This solution was filtered using 0.45 m 
membrane filter before analysis. The obtained final solution 
contained 25µg/ml SQXS.  
Forced degradation study on sulfaquinoxaline sodium water 
soluble powder 
The sample stock solutions were prepared by separately 
transferring 100 mg of the sulfaquinoxaline sodium water soluble 
powder (containing 250 mg SQXS per g) into series of five different 
100 ml volumetric flasks.  
The very same procedure adopted for the standard solutions was 
used in the sulfaquinoxaline sodium water soluble powder. The 
obtained final solution contained 25 µg/ml SQXS.  
RESULT AND DISCUSSION 
Method development and Optimization 
The proper choice of a stationary phase greatly depends on the 
chemical structure of the target pharmaceutical drug. Reversed 
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phase ODS column was first used at different acetonitrile (ACN) 
concentrations at fixed ammonium acetate (NH4AC) buffer ionic 
strength of 0.2M adjusted to pH 5.5. The SQXS peak eluted near to 
the void and no separation was obtained between the SQXS and 
SQXA even when the concentration of ACN reduced to 3.0%. 
Therefore, zwitterionic hydrophilic interaction liquid 
chromatography (ZIC-HILIC) was utilized to directly separate SQXS 
and SQXA without using any ion-pair reagent additives.  
The developed ZIC-HILIC-HPLC method was tested for the effect of 
ACN strength, pH, NH4AC concentration and temperature. Ionic 
strength of 50mM NH4AC concentration was increased up to 200mM 
with 50mM increment at fixed pH of 5.5. It was noticed that 
increasing the concentration of NH4AC improved the resolution 
between SQXS and SQXA through decreasing the retention time of 
SQXS and increasing the retention time of SQXA. Different pH values 
from 3.7 up to 7.2 with 0.5 increments were also tested. As the pH 
increased, the retention time of SQXS decreased and that of SQXA 
increased.  
The best tailing factor and resolution were obtained at pH of 5.7. The 
effect of acetonitrile strength on resolution and tailing factor of SQXS 
was investigated using 200mM NH4AC at pH of 5.7. As the ACN 
percent increased from 55% to 95% with 5% increment, the 
retention times of both SQXS and SQXA increased and the resolution 
improved.  
The best peak tailing factor and resolution with run time less than 
ten minutes were obtained at 90% ACN. Different temperatures of 
15C, 20C, 25C, 30C, and 35C were evaluated. Results indicate 
that temperature at this range does not play any substantial role in 
the retentions or the peaks shape of SQXS or SQXA and therefore a 
temperature of 25C was chosen during the entire study.  
The optimal mobile phase chosen with ZIC-HILIC column was an 
isocratic solvent mixture prepared by mixing 200 mM NH4AC 
solution and ACN (10:90; v/v), shaken well and left till the mobile 
phase reached to the room temperature. Then the pH was adjusted 
to 5.7 with glacial acetic acid. A wavelength of 263 nm was chosen 
since SQXS and SQXA were found to have maxima at this wavelength. 
Figure 2 and 3 show typical chromatogram of the placebo and 
freshly prepared system suitability solution of SQXS and SQXA used 
at the optimized conditions, respectively.  
 
Fig. 2: Zoomed view of typical placebo chromatogram. 
Method Validation 
The optimized ZIC-HILIC-HPLC method was validated as per 
ICH/USP guidelines. Parameters such as system suitability, 
specificity (placebo and forced degradation interferences), 
sensitivity (LOD and LOQ), linearity, range, accuracy (recovery), 
precision (repeatability and intermediate precision), robustness and 
stability indicating capability were validated. 
 
Fig. 3: Chromatogram of a standard mixture of SQXS (25 µg/ml) 
and SQXA (6µg/ml). 
System suitability 
The system suitability was determined by injecting successive six 
replicates of the same system suitability solution and analyzing the 
SQXS and SQXA for their peaks area, peaks USP tailing factor, 
resolution, number of theoretical plates and capacity factors. The 
system suitability results for a solution of 25 µg/ml SQXS and 
6µg/ml of SQXA revealed %RSD of 0.83% and 1.31% for peaks 
areas, respectively. This method meets the accepted requirements as 
set by the Palestinian Ministry of Health Registration Department 
(table 1). 
Table 1: Summary of the accepted system suitability 
requirements 
Parameter SQXS SQXA Accepted 
limit 
% RSD 0.83 1.31  2.0% 
Tailing factor (Tf) 1.28 1.36  2.0 
Resolution (Rs) --- 3.1 ≥2.0 
Number of theoretical 
plates (N) 
6235 26804 ≥2000 
Capacity factor (k') 2.9 3.9 ≥2.0 
Specificity (placebo and forced degradation interference)  
Generally the specificity of a method is its suitability for the analysis of a 
compound in the presence of potential impurities. Placebo, standard and 
sample test solutions were all injected at the same wavelength of 263 nm 
to assure the specificity of the optimized method. A comparison of the 
retention time of SQXS in sample solution and in the standard solution 
was exactly the same. Figures 2 and 3 showed that there is no 
interference at the retention time of SQXS due to the placebo. Therefore, 
the proposed method is suitable for the quantification of the SQXS in 
sulfaquinoxaline sodium water soluble powder.  The specificity of the 
method to SQXS was determined in the presence of its stress impurities. 
It was assessed by performing forced degradation studies on pure 
standards of the SQXS separately to indicate the initial results and on 
samples of sulfaquinoxaline sodium water soluble powder in presence of 
its potential degradants. The stress conditions studied are UV-light (254 
nm), heat (105C), acid hydrolysis (0.10 N HCl), base hydrolysis (0.10 N 
NaOH) and oxidation (3% H2O2). The stressed sample solutions were 
analyzed against freshly prepared standard and sample solutions. The 
assay and purity check for the stressed standard and sample solutions 
were calculated as summarized in Table 2. 
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Table 2: Summary of the forced degradation study 
Name Stress condition Degradation% Purity index* 
SQXS standard Acidic/0.10 N HCl / 60 min at RT 4.3 1.0000 
Alkaline/0.10 N NaOH / 60 min at RT  3.6 0.9997 
Oxidative/3.0% H2O2 /24 hours at RT 36.7 0.9991 
Thermal/105 °C/72 hours 8.8 0.9998 
Light/ UV-254nm /36 hours 8.2 1.0000 
SQXS sample Acidic/0.10 N HCl / 60 min at RT 4.4 0.9999 
Alkaline/0.10 N NaOH / 60 min at RT 3.7 0.9998 
Oxidative/3.0 % H2O2 /24 hours at RT 36.1 0.9994 
Thermal/105 °C/72 hours 9.0 1.0000 
Light/ UV-254nm /36 hours 8.3 1.0000 
* The accepted value is > 0.990 that set according to Palestinian Ministry of Health Registration Department criteria. The purity index is a measure 
of spectral heterogeneity of a peak. 
Table 2 revealed that the oxidative stress results showed extensive 
degradation in comparison to other stress conditions. Peak purity 
index for SQXS was found to be not less than 0.9991, a higher value 
than the accepted limit (0.990). Therefore, there was no interference 
between the SQXS peak and any other stress impurity peaks in the 
chromatogram. Almost the same pattern of degradation was 
obtained for SQXS in the Sulfaquinoxaline sodium water soluble 
powder samples. Figures (4-8) show the chromatographic profiles of 
the SQXS and the degradation products after exposing the 
Sulfaquinoxaline sodium water soluble powder to different stress 
conditions as in Table 2. 
 
Fig. 4: Chromatogram of SQXS water soluble powder upon 
exposure to UV-light 
 
Fig. 5: Chromatogram of SQXS water soluble powder upon 
exposure to heat 
 
Sensitivity 
The sensitivity of the method was explored via measuring the limit 
of detection (LOD) and the limit of quantitation (LOQ) for SQXS at a 
signal-to-noise ratio of 3 and 10 respectively. It has been achieved 
by injecting a series of SQXS diluted solutions with known 
concentrations. LOD was found to be 0.04 µg/ml. LOQ was found to 
be 0.13µg/ml with RSD of 3.8% (accepted value is less than 10%). 
 
Fig. 6: Chromatogram of acidic degradation of the SQXS water 
soluble powder 
 
Fig. 7: Chromatogram of basic degradation of the SQXS water 
soluble powder 
 
Fig. 8: Chromatogram of oxidative degradation of the SQXS 
water soluble powder, the peak at 10.485 minutes is due to 
H2O2. 
Linearity and range 
Different amounts of SQXS in the range of 50% to 150% of the 
labeled amount (5 concentration levels and 3 replicates each) were 
spiked to Sulfaquinoxaline sodium water soluble powder matrix 
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(Placebo). The linearity in the range of 12.5-37.5 µg/ml for SQXS was 
investigated. The regression line demonstrated linearity in the 
tested range. The regression analysis confirmed that the deviation of 
the y-intercept from zero is not significant; and the regression line 
was linear with R2 of 0.9998 (Fig.9, Table 3). 
 
Fig. 9: Linearity and range for SQXS 
 
Table 3: Regression statistics 
Active 
ingredient 
Linearity 
range 
(µg/ml) 
(R2 ) Linearity 
equation* 
Y-
intercept 
(%) 
SQXS 12.5-
37.5 
0.9998 Y=588947X+123574 0.84% 
*Y is the dependent variable and X is the independent variable 
Accuracy (recovery) 
Accuracy was determined by the recovery study of known amounts 
of SQXS standard added to a placebo matrix of water soluble powder 
dosage form. Different concentrations of the SQXS were added to 
placebo matrix and the recovery was measured. The accuracy as 
reflected from recovery data of the SQXS is listed in Table 4. The 
average recovery data of SQXS showed results between 98.9% and 
100.9% which are within the acceptable limit of (98.0 to 102.0% as 
set by the Palestinian Ministry of Health Registration Department 
criteria).  
 
Table 4: Average recoveries, % RSD values at five concentration 
levels of spiking of SQXS 
Active 
ingredient 
Amount added 
(level %) 
Average recovery 
(%) ± S.D 
(n=3) 
RSD 
(%) 
(n=3) 
SQXS 12.5 µg /ml 
(50%) 
18.75 µg /ml 
(75%) 
98.9 ± 0.41 
100.5± 0.87 
0.41 
0.87 
25.0 µg /ml 
(100%) 
31.25 µg /ml 
(125%) 
99.8 ± 1.12 
100.9 ± 0.76 
1.12 
0.75 
37.5 µg /ml 
(150%) 
99.5 ± 0.97 0.97 
Repeatability 
One laboratory analyst carried out the assay of SQXS on six 
determinations of homogeneous sample of Sulfaquinoxaline sodium 
water soluble powder dosage form at 100% level of the test 
concentration with the same analytical equipment at the same day. 
The assay results and statistical evaluation for assay of the SQXS 
revealed %RSD value of 0.77% which is within the acceptable limit 
of 2.0% (Set according to Palestinian Ministry of Health Registration 
Department criteria). 
Intermediate Precision (ruggedness) 
Two laboratory analysts carried out the assay of SQXS on twelve 
homogeneous samples of Sulfaquinoxaline sodium water soluble 
powder at 100% level of the final test concentration with two 
different analytical equipments on two different days. The assay 
results and statistical evaluation for assay of the SQXS revealed % 
RSD values of 1.46% which is within the acceptable limit of 2.0%. 
The results of the assay of the SQXS proved that the method is 
repeatable and rugged enough for day to day use.  
Robustness 
Premeditate variations were performed in the experimental 
conditions of the HPLC method to assess its robustness. The six 
variations imposed to the chromatographic method are 
summarized in Table 5. The modifications include different 
mobile phase flow rates of 0.45, 0.50, and 0.55 ml/min and three 
different column temperatures in the range 22-28C. Different 
NH4AC solution concentrations in mobile phase (190mM, 200mM 
and 210mM) and different ACN percentages in mobile phase 
(88%, 90% and 92%) were also investigated. Two column 
batches filled with the same prescribed stationary phases were 
studied. Finally, three different pH values of the mobile phase at 
5.5, 5.7, and 5.9 were tested. The assay results of SQXS showed 
results between 98.8% and 101.1% which are within the 
acceptable limit of (98.0 to 102.0%) (Table 5).  
 
Table 5: Robustness testing of the SQXS active ingredient 
Active 
ingredient 
Parameter 
 
Modification Average 
assay%±S.D 
(n=3) 
SQXS  Flow rate 
(ml/min) 
Mobile phase 
ratio (v/v) 
NH4AC: ACN 
 
0.45 
0.50 
0.55 
12:88 
10:90 
8:92 
100.4 ± 0.94 
100.2 ± 1.07 
99.7 ± 1.21 
98.8 ± 0.88 
99.9 ± 1.14 
100.1 ± 1.21 
Temperature 
(oC) 
22 
25 
28 
99.3 ± 0.96 
100.3 ± 1.18 
99.6 ± 0.98 
NH4AC 
Conc.(mM) 
 190 
200 
210 
99.7 ± 1.06 
100.5 ± 0.91 
99.1 ± 0.84 
Mobile phase 
pH 
 
5.5 
5.7 
5.9 
99.8 ±1.27 
99.4 ±0.97 
101.1 ±0.73 
Column 
batches 
L010129977 
L010134877 
99.4 ± 0.96 
100.3 ± 1.17 
 
CONCLUSION 
The validated HPLC method developed for the quantitative quality 
control determination of Sulfaquinoxaline sodium in its water 
soluble powder was evaluated over system suitability, specificity, 
sensitivity, linearity, range, accuracy (recovery), precision 
(repeatability and intermediate precision) and robustness. All the 
validation results were within the allowed specifications of ICH/USP 
guidelines. The developed method proved to be accurate, very 
sensitive and stability indicating for the determination of the 
Sulfaquinoxaline sodium in its water soluble powder in the presence 
of excipients, SQXA and other degradation products. The assay 
showed complete separation of SQXS from SQXA, from other 
degradation products and from the placebo. As a result, the 
proposed ZIC-HILIC-HPLC method could be adopted for quantitative 
quality control and routine analysis of Sulfaquinoxaline sodium 
water soluble powder. 
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